Bladder Carcinoma | Cancer Search

Details 116 Trials 4 Therapies

A carcinoma arising from the bladder epithelium. Approximately 90% of the bladder carcinomas are transitional cell carcinomas. The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.

parent conditions

Carcinoma

Malignant Bladder Neoplasm

child conditions

Bladder Small Cell Neuroendocrine Carcinoma

Bladder Urothelial Carcinoma

Bladder Urachal Carcinoma

Bladder Squamous Cell Carcinoma

Bladder Adenocarcinoma

Non-Muscle Invasive Bladder Carcinoma

synonyms

Bladder Cancer

Bladder Carcinoma

Cancer of Bladder

Carcinoma of Bladder

Cancer of the Bladder

Urinary Bladder Cancer

Bladder carcinoma (NOS)

Carcinoma of the Bladder

Cancer of Urinary Bladder

Urinary Bladder Carcinoma

Carcinoma of Urinary Bladder

Cancer of the Urinary Bladder

Carcinoma of the Urinary Bladder

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin

194 sites for NCT04960709

Bladder Urothelial Carcinoma

durvalumab, +3 more drugs

chemotherapy, +3 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

94 sites for NCT04700124

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

245 sites for NCT04637594

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

154 sites for NCT04165317

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

131 sites for NCT03711032

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

178 sites for NCT03661320

Bladder Carcinoma

cisplatin, +3 more drugs

chemotherapy, +1 more type

Show 116 Trials for Bladder Carcinoma

pembrolizumab

Bladder Urothelial Carcinoma In Situ